clinical trial · NCT01671774
Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer
Astellas Pharma Global Development, Inc.·phase1·completed·n = 29
CLDN18.2-positive Gastric AdenocarcinomaCLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionCLDN18.2-positive Adenocarcinoma of EsophagusIMAB362Zoledronic acidInterleukin-2 (1 million IU)Interleukin-2 (3 million IU)
brief summary
The purpose of the trial is to assess the immunological effects and their kinetics, the safety and activity of IMAB362 plus Zoledronic acid with/without low to intermediate doses of Interleukin-2 in subjects with advanced gastroesophageal cancer.
started
Oct 16, 2012
primary completion
Oct 13, 2014
completion
Oct 13, 2014
last updated
Nov 14, 2024
official title
Multicenter, Open-label, Exploratory Phase I Pilot Study to Investigate Safety, Pharmacodynamics, and Pharmacokinetics of Immunological Effects and Activity of Combining Multiple Doses of IMAB362 With Immunomodulation (Zoledronic Acid, Interleukin-2) in Patients With Advanced Adenocarcinoma of the Stomach, the Lower Esophagus, or the Gastroesophageal Junction
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol